Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials (original) (raw)

This paper discusses the optimization of imatinib dosing for the treatment of gastrointestinal stromal tumors (GIST) based on findings from phase 3 clinical trials. GISTs are primarily resistant to conventional therapies, and imatinib has significantly improved patient outcomes since its introduction as a targeted therapy. The analysis of the phase 3 studies reveals that while the standard starting dose is 400 mg/d, higher doses, particularly 800 mg/d, were evaluated for efficacy and safety, demonstrating a potential for improved progression-free survival, particularly in patients with specific genetic mutations. The results underscore the importance of personalized treatment strategies in optimizing therapeutic outcomes for GIST patients.